New hope for stomach cancer: immunotherapy combo targets resistant tumors
NCT ID NCT07259473
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial will test a combination of immunotherapy drugs and chemotherapy given before surgery for people with a specific genetic subtype of stomach cancer (dMMR/MSI-H). The study aims to see how well this approach clears the tumor and to understand why some patients do not respond. It will enroll 15 adults in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Immune checkpoint inhibitors (PD-1/PD-L1/CTLA-4 antibodies) plus oxaliplatin chemotherapy
What this could lead to
If successful, this could point toward a more effective treatment strategy for Asian patients with this specific type of gastric cancer, potentially increasing the chance of complete tumor removal.
What could go wrong
This is a very small early-phase trial (15 people) and results may not apply to all patients. About half of patients with this cancer type do not respond to immunotherapy, and the study may not uncover why.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••